Global Acinetobacter Infections Treatment Market Growth (Status and Outlook) 2023-2029

Global Acinetobacter Infections Treatment Market Growth (Status and Outlook) 2023-2029

Acinetobacter is a group of bacteria commonly found in soil and water. While there are many types or “species” of Acinetobacter and all can cause human disease, Acinetobacter baumannii accounts for about 80% of reported infections.

Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings.

Acinetobacter is often resistant to many commonly prescribed antibiotics. Decisions on treatment of infections with Acinetobacter should be made on a case-by-case basis by a healthcare provider. Acinetobacter infection typically occurs in ill patients and can either cause or contribute to death in these patients.

LPI (LP Information)' newest research report, the “Acinetobacter Infections Treatment Industry Forecast” looks at past sales and reviews total world Acinetobacter Infections Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Acinetobacter Infections Treatment sales for 2023 through 2029. With Acinetobacter Infections Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Acinetobacter Infections Treatment industry.

This Insight Report provides a comprehensive analysis of the global Acinetobacter Infections Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Acinetobacter Infections Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Acinetobacter Infections Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Acinetobacter Infections Treatment and breaks down the forecast by type, by pipeline, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Acinetobacter Infections Treatment.

The global Acinetobacter Infections Treatment market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

In the American market, Major manufacturers include Entasis Therapeutics, Roche, Adenium Biotech, Vaxdyn, Hsiri Therapeutics, Aridis Pharmaceuticals, and Legochem Biosciences, Atterx Biotherapeutics, Achaogen, Peptilogics, Sealife Pharma, Shionogi, Techulon and Tetraphase Pharmaceuticals, among others. Entasis Therapeutics, Roche and Adenium Biotech are the top 3 players of Acinetobacter Infections Treatment, with about 66% market shares.

This report presents a comprehensive overview, market shares, and growth opportunities of Acinetobacter Infections Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type

Sulbactam

Carbapenems

Aminoglycosides

Polymyxins

Tetracyclines

Others

Segmentation by pipeline

ETX2514

Nacubactam RG6080

Arenicin

VXD-001

Small Molecule Antibiotic

AR-401 mAB

LCB01-0371 (PO)

GN-4474

Antibacterial Antibody

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Entasis Therapeutics

Roche

Adenium Biotech

Vaxdyn

Hsiri Therapeutics

Aridis Pharmaceuticals

LegoChem Biosciences

Atterx Biotherapeutics

Achaogen

Peptilogics

Sealife PHARMA

Shionogi

Techulon

Tetraphase Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.